Fel rhan o hyn, mae dros 100 o wledydd wedi galw am atal dros dro rwymedigaethau rhyngwladol sy’n diogelu hawliau eiddo deallusol mewn perthynas â brechlynnau Covid-19. Caiff y rhwymedigaethau hyn eu diffinio o dan Gytundeb ar Agweddau ar Hawliau Eiddo Deallusol sy'n Gysylltiedig â Masnach (TRIPS) Sefydliad Masnach y Byd (WTO). Byddai eu hepgor dros dro yn caniatáu ehangu mynediad hanfodol at batentau sy’n angenrheidiol i weithgynhyrchu brechlynnau Covid-19 yn ddiogel ac yn effeithlon mewn gwledydd sy’n datblygu. Ac eto, er bod cefnogaeth fyd-eang ar gynnydd, a bod datrysiad cyfaddawdol wedi’i gynnig rhwng yr UE, yr Unol Daleithiau, India a De Affrica, mae grŵp bach o wledydd, y mwyafrif ohonynt yn rhai incwm uchel, gan gynnwys y DU, yn parhau i wrthwynebu hepgor y rhwymedigaethau hyn.
As part of this solution, more than 100 countries have called for the temporary suspension of international obligations to protect intellectual property rights, defined under the World Trade Organisation (WTO) TRIPS agreement, in relation to Covid-19 vaccines. This temporary waiver would allow for the expansion of critical access to patents necessary to safely and efficiently manufacture Covid-19 vaccines in developing countries. Yet, despite growing global support, and a compromise solution being tabled between the EU, US, India and South Africa, a waiver continues to be opposed by a small group of predominantly high-income countries, including the UK.